Hetero, Zydus Settle Novartis MS Drug Suits Before IP Trial
By Dani Kass · March 2, 2020, 4:18 PM EST
Generic-drug makers Hetero and Zydus have each reached last-minute settlements to avoid an infringement trial set for Monday over their versions of Novartis Pharmaceuticals Corp.'s blockbuster multiple sclerosis drug Gilenya....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login